Pharmacovigilance Outsourcing vs In-House: Which Model Fits Your Case Volume?

Choosing between in-house and outsourced pharmacovigilance is not simply a question of comparing salaries with a vendor’s rate card. The right model depends on case volume, workload variability, internal expertise, systems, governance capacity and the sponsor’s ability to oversee delegated work.

For many organisations, the practical choice is a hybrid model. The sponsor retains control of its pharmacovigilance system and key decisions, while a vendor provides operational capacity. The question is where that boundary should sit, and whether the total cost and oversight demands make sense for your products and markets.

Start with the work, not the headcount

Pharmacovigilance outsourcing has become a routine operating choice. In some organisations, more than half of day-to-day PV operations may be handled externally. However, there is no single audited global census of outsourced PV activity, so treat that estimate as directional rather than a universal benchmark.

Case volume is an important starting point, but it does not tell the whole story. Assess the number and mix of cases: initial and follow-up reports, serious cases, solicited reports, literature cases, languages, markets and expected medical-review requirements. Then map the other work in scope, including signal management, aggregate reporting pharmacovigilance, risk management plans, PSMF maintenance and inspection support.

Practical takeaway: Build a workload profile by task and case type. Avoid using a single annual case count to represent the effort, complexity or risk of your whole PV operation.

Compare total cost of ownership

A vendor’s per-case fee or FTE rate is only one part of the cost. A fair comparison should account for the resources needed to deliver the work, maintain quality and keep the system inspection-ready.

In-house costs to include	Outsourced costs to include
Salaries, benefits, recruitment and training	Retainers, case fees or FTE charges
Safety database, licences and system validation	Technology, integration and validation charges
Quality assurance, management and facilities	Sponsor oversight, audits and inspection support
Overtime, leave cover and business continuity	Transition, change requests, rework and volume changes

Also model costs that cross the boundary, such as medical review, follow-up, submissions, reconciliation and data transfers. Calculate cost per completed, quality-accepted case, not just per case received. A low quoted rate may not remain low if exclusions, rework or follow-up fees are substantial.

Practical takeaway: Compare low, expected and peak-volume scenarios. Include transition and oversight costs, and make every bidder state what is included, excluded and charged separately.

Understand the pricing model

Two common approaches are per-case and FTE-based pricing. Some contracts combine them.

Per-case pricing can make costs easier to relate to volume. The agreement needs a clear definition of a billable case and different rates, if relevant, for initial and follow-up cases, serious cases, literature reports, translations, medical review and submissions. Clarify how the vendor charges for incomplete or duplicate reports and rework.

FTE pricing may suit work that is difficult to count case by case, such as medical assessment, signal management or ongoing compliance support. It can also suit stable, predictable operations. Define the roles, seniority, productive capacity, coverage hours, backup arrangements and how workload increases are handled.

Practical takeaway: Ask vendors to price the same workload assumptions and service boundaries. Where appropriate, combine a defined base capacity with variable case charges, and set a process for approving any additional work.

Decide what stays under sponsor control

Delegating tasks does not mean delegating accountability. Under EU GVP, the marketing authorisation holder (MAH) retains responsibility for its pharmacovigilance obligations and for the quality and integrity of its system, even when tasks are subcontracted. The QPPV needs meaningful oversight and access to relevant system information.

Many sponsors retain ownership of decisions and controls such as:

• PV system governance, escalation and oversight of the QPPV.
• Safety strategy and benefit-risk decisions.
• Approval of signal assessments, risk management actions and safety communications.
• Control of regulatory commitments, product information changes and significant authority responses.
• Vendor qualification, audit planning and review of quality performance.

A vendor can provide analysis, recommendations and operational support. The sponsor should define who assesses, who recommends, who approves and who communicates.

Practical takeaway: Create a responsibility matrix for each PV process. Keep the decision rights and escalation routes clear, including who has authority to act when a safety concern requires prompt attention.

Put governance into the contract

The contract and safety data exchange agreement should describe the work in enough detail to be usable during routine operations and inspection. EU GVP Module III Revision 2 took effect on 10 September 2026 and addresses subcontracting in the context of pharmacovigilance inspections. Competent authorities may inspect parties performing PV tasks, including further subcontractors. The MAH should be able to understand and govern the subcontracting chain.

Include provisions covering:

• Subcontractors: prior approval or notification, names and locations, delegated activities, oversight and inspection arrangements.
• Audit and inspection rights: access to relevant staff, records, systems and facilities; cooperation with authority inspections; and timely provision of documents.
• Data ownership and access: sponsor ownership or control of safety data, access to records, retention, return or transfer at contract end, and business continuity.
• Data access and sharing: define the relevant DA/DSA arrangements, permitted purposes, data flows, security responsibilities, reconciliation and handling of corrections.
• Change control: notify the sponsor of material changes to systems, processes, staffing, locations or subcontractors.
• Quality management: deviation reporting, investigation, CAPA, escalation and approval responsibilities.

For any PSMF audit pharmacovigilance review, the sponsor should be able to explain which activities are delegated, where they are performed and how the quality system monitors them.

Practical takeaway: Have PV, quality, regulatory, IT/security and legal teams review the operating model and contract together. A clause granting audit rights is only useful if the vendor can make those rights work across its delivery chain.

Write measurable quality metrics into the agreement

KPIs should reflect patient-safety obligations and service quality, not just productivity. Agree definitions, data sources, exclusions, reporting frequency, thresholds and escalation steps before work starts.

Consider measuring:

• Case processing and submission timeliness against applicable requirements.
• Case data completeness and accuracy, including agreed sampling methodology.
• Follow-up completion and the age of cases awaiting information.
• Duplicate handling, reconciliation completion and backlog.
• Quality deviations, repeat errors, CAPA timeliness and effectiveness.
• Training completion, staff turnover and continuity of coverage.
• Timeliness of signal, aggregate reporting pharmacovigilance and other deliverables, where in scope.

Set targets based on your case mix, regulatory timelines and risk tolerance. Avoid adopting generic percentages without checking whether they fit the service. Define how the parties will investigate a missed target and when an issue must be escalated to the sponsor’s PV lead or QPPV.

Practical takeaway: Make the KPI schedule operational: specify the calculation, owner, evidence, review cadence and consequence of a recurring or critical failure.

Plan for transition and volume peaks

A contract award does not create operational readiness. Transition requires process mapping, data transfer, system access, training, reconciliation, testing and a controlled cutover. Knowledge that exists only with a few experienced team members can be lost during migration or vendor change.

Capacity planning should include both routine demand and foreseeable peaks: product launches, acquisitions, safety issues, label changes, campaigns and seasonal effects. Agree surge capacity, lead times, backup coverage and how the vendor will prioritise urgent work.

Regulatory technology readiness is also a procurement issue. From 1 October 2026, FDA requires postmarketing ICSRs for specified human drugs, biological products and drug- or biologic-led combination products submitted through ESG NextGen to use ICH E2B(R3). Ask who owns mapping, testing, submission acknowledgements, rejection handling and change control. FDA says the requirement applies to ESG NextGen; its Safety Reporting Portal route is not affected by this notice.

Practical takeaway: Require a documented transition and surge plan. Confirm E2B(R3) responsibilities and evidence of readiness before the relevant submission route is in use.

Choose the model that fits your operating profile

An in-house model may suit organisations with steady, substantial workloads and the systems and specialist staff to support them. An outsourced model can provide access to capacity and expertise without building every operational capability internally, but it requires active governance. A hybrid model can combine outsourced processing capacity with sponsor-owned oversight and decision-making.

No model removes the need to understand the work, monitor quality or plan for disruption. The strongest decision is based on total cost, workload variability, internal capability and the sponsor’s ability to control the PV system.

Practical takeaway: Score each model against cost, quality, oversight, capacity, resilience and strategic control. Revisit the decision when products, markets or case volumes change.

Continue the discussion in Chennai

Pharmacovigilance outsourcing involves both sponsor-side governance and service-provider delivery. On 29 July 2027, Pharmacovigilance India 2027 brings senior drug safety decision-makers and PV service providers together for a one-day conference in Chennai, with sessions on outsourcing partnerships, inspection readiness, PSMF and audits, signal management and related operational challenges.

Learn about Pharmacovigilance India 2027, view ticket options or explore sponsorship opportunities.